Gene expression studies of TAMs treated with ruxolitinib showed that mammary tumor cells activate the JAK/STAT pathway in TAMs via secreted soluble factors, and thereby activate several tumor promoting pathways such as the TNF signaling pathway, PI3-Akt signaling pathway, VEGF signaling pathway65,66. This evidence concerns the gene PI3 and breast cancer.